Spacer
Spacer Home  |  Contact Us Spacer
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.
spacer
Banner for News pages
spacer
spacer

Press Releases

2013
October 29, 2013
Alvine Pharmaceuticals Doses First Patient in Phase 2B Trial for ALV003 in Celiac Disease

May 14, 2013
AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease

2012
October 24, 2012
Alvine Pharmaceuticals Presents Celiac Disease Symptom Frequency and Severity Study Results at the 2012 American College of Gastroenterology Meeting

September 5, 2012
Alvine’s ALV003 Receives Fast Track Designation From the FDA for Potential Treatment of Celiac Disease

May 22, 2012
Alvine Pharmaceuticals Presents Results from a Phase 2A Trial of ALV003 in Celiac Disease Patients at the 2012 Digestive Diseases Week Meeting

2011
November 29, 2011
Alvine’s ALV003 Named a Top 10 Inflammatory/Autoimmune Project to Watch by Windhover for a Rare Second Year

October 24, 2011
Alvine Pharmaceuticals Presents Additional Efficacy Data from Phase 2a Trial of ALV003 in Celiac Disease Patients

October 11, 2011
Alvine Pharmaceuticals Announces Positive Results from Phase 2a Trial of ALV003 in Celiac Disease Patients

September 22, 2011
Alvine Pharmaceuticals Announces Upcoming Presentation of Phase 2a ALV003 Data in Patients with Celiac Disease

September 13, 2011
Alvine Pharmaceuticals Appoints James D. Watson As Senior Vice President And Chief Business Officer

May 18, 2011
Alvine Pharmaceuticals Announces Issuance Of US Patents For Enzyme Use In Celiac Disease

2010
November 2, 2010
Alvine Pharmaceuticals’ ALV003 Named A Top 10 Inflammatory/Autoimmune Project To Watch By Windhover

May 26, 2010
Alvine Pharmaceuticals Announces Equity Investment by Abbott Biotech Ventures Inc.

May 4, 2010
Alvine Pharmaceuticals Presents Data on the Effects of ALV003 in a Gastric Model That Predicts In Vivo Activity at DDW 2010

2009
November 11, 2009
Alvine Pharmaceuticals to Present at Lazard Healthcare Conference in New York

September 15, 2009
Alvine Pharmaceuticals Raises $21.5 Million Series A Extension

August 25, 2009
Alvine Initiates Enrollment in Phase 2a Clinical Trial of ALV003 for Use in the Treatment of Celiac Disease

March 19, 2009
Alvine Pharmaceuticals Appoints Dr. Daniel C. Adelman, M.D., as Senior Vice President and Chief Medical Officer

January 07, 2009
Alvine Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference

2008
October 29, 2008
Alvine Pharmaceuticals Reports Positive Results With Alv003 In Phase 1 Trial Of Therapy In Development For Celiac Disease

February 21, 2008
Alvine Pharmaceuticals Obtains Patents for Celiac Disease Therapies

February 13, 2008
Alvine Pharmaceuticals Initiates Phase I Trial for ALV003


View Archive


Back To Top
 

www.clinicaltrials.gov >>   

spacer
spacer

Location

Alvine Pharmaceuticals, Inc.
Headquarters
75 Shoreway Rd., Suite B
San Carlos, CA 94070
view all contact info >>

Business Inquiries

Kirk Essenmacher, M.D., M.B.A.
T: (650) 596-2434
E: email BD >>

Clinical Inquiries

E: email info@alvinepharma.com >>

spacer
spacer